U.S. markets close in 6 hours 14 minutes
  • S&P 500

    4,267.62
    +25.78 (+0.61%)
     
  • Dow 30

    34,147.56
    +273.32 (+0.81%)
     
  • Nasdaq

    14,375.40
    +103.67 (+0.73%)
     
  • Russell 2000

    2,318.78
    +15.31 (+0.66%)
     
  • Crude Oil

    72.63
    -0.45 (-0.62%)
     
  • Gold

    1,784.30
    +0.90 (+0.05%)
     
  • Silver

    26.18
    +0.07 (+0.26%)
     
  • EUR/USD

    1.1953
    +0.0020 (+0.17%)
     
  • 10-Yr Bond

    1.4900
    +0.0030 (+0.20%)
     
  • GBP/USD

    1.3927
    -0.0037 (-0.26%)
     
  • USD/JPY

    110.7580
    -0.2040 (-0.18%)
     
  • BTC-USD

    34,028.42
    -125.49 (-0.37%)
     
  • CMC Crypto 200

    818.61
    +31.99 (+4.07%)
     
  • FTSE 100

    7,108.95
    +34.89 (+0.49%)
     
  • Nikkei 225

    28,875.23
    +0.34 (+0.00%)
     

FGEN DEADLINE REMINDER: Kessler Topaz Meltzer & Check, LLP - Important June 11, 2021 Deadline Reminder for FibroGen, Inc. Investors

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

Radnor, Pennsylvania--(Newsfile Corp. - May 25, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") that a securities fraud class action lawsuit has been filed against on behalf of those who purchased or acquired FibroGen securities and/or sold put options from October 18, 2017 through April 6, 2021, inclusive (the "Class Period").

Lead Plaintiff Deadline: June 11, 2021
Website: https://www.ktmc.com/fibrogen-class-action-lawsuit?utm_source=PR&utm_medium=Link&utm_campaign=fibrogen
Contact: James Maro, Esq. (484) 270-1453
Adrienne Bell, Esq. (484) 270-1435
Toll free (844) 887-9500

FibroGen is a biopharmaceutical company that develops medicines for the treatment of anemia, fibrotic disease, and cancer. Its most advanced product is roxadustat ("Roxa"), an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylase activity that acts by stimulating the body's natural pathway for red cell production.

The complaint alleges that throughout the Class Period, the defendants made false and/or misleading statements or failed to disclose that: (1) based on the safety data from FibroGen's two Phase 3 trials in China, any safety data obtained from the global Phase 3 trials would require post-hoc changes to the stratification factors to meet the U.S. Food and Drug Administration's ("FDA") requirements; (2) FibroGen's disclosures of U.S. primary cardiovascular safety analyses from the Roxa global Phase 3 program for the treatment of anemia submitted in connection with chronic kidney disease ("CKD") included post-hoc changes to the stratification factors; (3) FibroGen's analyses with the pre-specified stratification factors resulted in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (4) based on these analyses, FibroGen could not conclude that Roxa reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (5) as a result, FibroGen faced significant uncertainty that its NDA for Roxa as a treatment for anemia of CKD would be approved by the FDA; and (6) as a result of the foregoing, the defendants' statements about FirboGen's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

FibroGen investors may, no later than June 11, 2021, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP, or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(844) 887-9500 (toll free)
info@ktmc.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/85124